

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

LONDON



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE TREATY OF COOPERATION IN PATENT MATTERS (PCT)

(51) International Patent Classification <sup>5</sup> : <b>A61K 47/48</b>		<b>A1</b>	(11) International Publication Number: <b>98/35705</b>
		(43) International Publication Date: <b>20.08.98</b>	
(21) International Application Number: <b>PCT/US98/03033</b>		(74) Agents: CRANAHAN, Patricia et al. / Brock, Smith & Reynolds, P.C., Two Natick Drive, Natick, MA 02173 (US).	
(22) International Filing Date: <b>18 February 1998 (18.02.98)</b>		(81) Designated States: CA, US, European patent AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, JP, MC, NL, PT, SE.	
(30) Priority Data: 60/038,059      18 February 1997 (18.02.97)      US 60/066,288      25 November 1997 (25.11.97)      US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US      60/066,288 (CON) Filed on      25 November 1997 (25.11.97) US      60/038,059 (CON) Filed on      18 February 1997 (18.02.97)			
(71) Applicant (for all designated States except US): WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): YOUNG, Richard, A. [US/US]; 216 Highland Street, Weston, MA 02193 (US).			
(54) Title: USE OF HEAT SHOCK PROTEINS TO DELIVER MOIETIES INTO CELLS			
(57) Abstract  The present invention relates to a method of delivering a moiety of interest into a cell comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell. The invention also relates to a method of delivering a moiety of interest into a cell capable of taking up a complex comprising the moiety of interest covalently linked to a heat shock protein comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell. Also encompassed by the present invention is a method of delivering a moiety of interest into an antigen presenting cell comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell.			

A03

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

USE OF HEAT SHOCK PROTEINS TO  
DELIVER MOIETIES INTO CELLS

GOVERNMENT SUPPORT

The invention was supported, in whole or in part, by  
5 grants AI26463 and AI31869 from The National Institutes of  
Health. The Government has certain rights in the  
invention.

RELATED APPLICATIONS

This application claims the benefit of U.S.  
10 Provisional Application No. 60/039,059, filed February 18,  
1997 and U.S. Provisional Application No. 60/066,288, filed  
November 25, 1997, the contents of which are incorporated  
herein by reference in their entirety.

BACKGROUND

15 The cytotoxic T lymphocytes (CTL) that play an  
important role in protective cellular immunity, including  
the destruction of virus-infected cells, are predominantly  
CD8 T cells (Byrne, J.A. & Oldstone, M.B., *J. Virol.*,  
51:682-686 (1984); Nagler-Anderson, C. et al., *J. Immunol.*,  
20 141:3299-3305 (1988)). Antigen-specific activation of  
these cells depends upon their recognition of peptide-MHC  
complexes, which normally arise within antigen presenting  
cells by proteolytic cleavage of cytosolic proteins  
(Townsend, A. & Bodmer, H., *Annu. Rev. Immunol.*, 7:601-624

-2-

(1989)). Translocated into the ER, the resulting peptides bind to nascent class I MHC molecules for transport to the cell surface (Heemels, M.T. & Ploegh, H., *Annu. Rev. Biochem.*, 64:463-491 (1995)). However, many intact and/or functional molecules such as proteins cannot ordinarily penetrate into a cell's cytosol on their own.

## SUMMARY OF THE INVENTION

The present invention relates to a method of delivering a moiety of interest (e.g., protein, lipid) into a cell comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein (hsp) (e.g., a mycobacterial hsp), under conditions appropriate for entry of the complex into the cell. The complex can comprise the moiety of interest conjugated to the hsp. Alternatively, the complex can comprise the moiety fused to the hsp. These two embodiments of complexes of the present invention are referred to, respectively, as hsp-moiety of interest conjugates and hsp-moiety of interest fusions.

In one embodiment, the present invention relates to a method of delivering a moiety of interest into a cell capable of taking up a complex comprising the moiety of interest covalently linked to a heat shock protein, comprising contacting the cell with the complex, under conditions appropriate for entry of the complex into the cell.

In another embodiment, the present invention relates to a method of delivering a moiety of interest into an antigen presenting cell comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell.

The present invention also relates to a method of delivering a moiety of interest into a cell of an

-3-

individual (e.g., human) comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell.

5 In one embodiment, the present invention relates to a method of delivering a moiety of interest into a cell of an individual wherein the cell is capable of taking up a complex comprising the moiety of interest covalently linked to a heat shock protein, comprising contacting the cell  
10 with the complex, under conditions appropriate for entry of the complex into the cell.

In another embodiment, the invention relates to a method of delivering a moiety of interest into an antigen presenting cell of an individual comprising contacting the  
15 cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1A is a graph of effector cells to target cells  
20 (E:T) ratios versus % specific lysis showing generation of ovalbumin-specific CTL by immunization with ova-hsp70 fusion protein in saline.

Figure 1B is a graph of log [SIINFEKL] versus %  
specific lysis showing a SIINFEKL peptide (SEQ ID NO: 1)  
25 titration, wherein T2-K<sup>b</sup> cells were incubated with the indicated molar concentrations of SIINFEKL peptide (SEQ ID NO: 1) for 45 minutes for use as target cells in a CTL assay.

Figures 2A-2C are graphs of E:T ratios versus %  
30 specific lysis demonstrating that immunization with ova-hsp70 elicits ovalbumin reactive CD8<sup>+</sup> T cells.

Figure 3A is a bar graph showing IFN- $\gamma$  secretion by splenocytes stimulated 72 hours in vitro with 5  $\mu$ g/ml

-4-

recombinant ova protein ■, SIINFEL peptide (SEQ ID NO: 1) (hatched box), RGYVYQGL peptide (SEQ ID NO: 2) (lightly shaded box), or tissue culture media alone □; all samples were examined in triplicate.

5        Figure 3B is a graph of E:T ratios versus % specific lysis showing generation of ova-specific CTL by immunization with ova-hsp70 fusion protein in saline.

10        Figures 4A-4B are graphs of days versus tumor diameter, wherein, following the M05 (Figure 4A) and B16 (Figure 4B) tumor challenges, tumor growth was monitored in control mice Δ and in ova □ and ova-hsp70 ■ immunized mice, and recorded as the average tumor diameter in millimeters.

15        Figure 4C is a graph of days versus % survival wherein the survival of mice was recorded as the percentage of mice surviving following the tumor challenge; mice which appeared moribund were killed and scored as 'not surviving'.

#### DETAILED DESCRIPTION OF THE INVENTION

20        The present invention relates to a method of delivering moieties or molecules (e.g., proteins, peptides, lipids) which are not generally able to enter cells or which enter cells only to a limited extent, into cells or into cells of an individual, and to complexes, including hsp-moiety of interest conjugates and hsp-moiety of  
25        interest fusions, such as protein complexes or fusion proteins, useful in the method. As a result of the present method, a functional molecule (e.g., a biologically active molecule) is delivered into cells. As described herein, Applicant has shown that covalently coupling a heat shock  
30        protein (hsp), such as a mycobacterial hsp, to a moiety which cannot enter mammalian cells on its own or which enters mammalian cells on its own only to a limited extent, results in delivery of the moiety into cells. As described herein, the ability of an hsp present in a complex



-5-

comprising the hsp linked to a moiety of interest, to elicit MHC class I-restricted CTLs against the attached moiety indicates that the complex is able to enter cells, as an intact molecule, and enter the class I antigen presentation pathway of the cell. Thus, the methods of the present invention can be used to deliver a moiety which is not generally able to enter cells or which enters cells only to a limited extent, into cells (e.g., of an individual) which are able to take up the complexes (such as cells having an MHC class I antigen presentation pathway).

Moietyies such as proteins, peptides, lipids, glycoproteins, small organic molecules and other molecules, particularly chemicals, and other molecules which are useful therapeutically or diagnostically, are delivered into mammalian cells by the present method. For example, a fusion protein comprising a hsp linked or coupled to a moiety to be delivered into cells is administered to/introduced into a mammal, such as a mouse, monkey or human, as a soluble protein using known techniques and routes of administration. Alternatively, an hsp-moiety of interest conjugate can be introduced into cells. The moiety to be delivered enters cells as a result of the ability of the hsp component to enter cells or chaperone entry of the moiety into cells.

As described herein, a complex comprising a moiety of interest and an hsp is delivered into cells. The hsp can be conjugated or joined to the moiety of interest to form a single unit. In one embodiment, the hsp is conjugated to the moiety of interest, such as by chemical means, to produce an hsp-moiety of interest conjugate. In another embodiment, the hsp is fused to the moiety of interest, such as by recombinant techniques (e.g., expression of the hsp and moiety of interest by recombinant DNA techniques). Conjugation can be achieved by chemical means known to

-5-

those skilled in the art (e.g., through a covalent bond between the hsp and the moiety; reductive amination). If recombinant techniques are used to link the hsp and the moiety, the result is a recombinant fusion protein which includes the hsp and the moiety in a single molecule. This makes it possible to produce and purify a single recombinant molecule.

In a specific embodiment, a fusion protein comprising a mycobacterial hsp covalently linked to a peptide or protein is injected into a mammal, in which the fusion protein enters cells. For example, a fusion protein comprising a mycobacterial hsp and a moiety to be delivered into mammalian cells is injected as a soluble protein into a mammal (e.g., mouse, human) and the fusion protein enters the cells of the mammal. Thus, moieties such as whole proteins or peptides which typically do not enter cells efficiently, but which are functional entities once inside cells, are complexed to an hsp in order to efficiently introduce the moiety into cells. Similarly, chemicals which do not enter cells efficiently can be introduced into target cells by being complexed to hsps. Another example of the present invention is a fusion protein comprising an hsp and a functional molecule, such as a cellular protease, which is administered to a mammal and processed by cells of the mammal, thereby releasing a functional molecule (e.g., the protease) from the fusion once it enters the cell.

As used herein the term "heat shock protein" or "hsp", also known as "stress protein", is a protein which is synthesized in an organism in response to stresses to the organism, such as a rise in temperature and/or glucose deprivation. In particular embodiments, the hsp used in the methods of the present invention is an isolated (purified, essentially pure) hsp. The hsp can be isolated from the cell in which it occurs in nature using routine methods. In addition, the hsp can be produced using

-7-

chemical or recombinant techniques (Maniatis et al.,  
Molecular Cloning, A Laboratory Manual, 2nd ed. Cold  
Spring Harbor Laboratory Press, 1989). The term "hsp" also  
includes the entire hsp or a portion of the hsp of  
5 sufficient size to deliver or chaperone entry of a moiety  
into a cell. The term "hsp" also includes a protein having  
an amino acid sequence which is the functional equivalent  
of the hsp in that it is sufficiently homologous in amino  
acid sequence to that of the hsp to be capable of  
10 delivering or chaperoning entry into a cell of a moiety  
which does not enter cells on its own or enters cells on  
its own only to a limited extent. The term "sufficiently  
homologous in amino acid sequence to that of the hsp" means  
that the amino acid sequence of the protein or polypeptide  
15 will generally show at least 40% identity with the hsp  
amino acid sequence; in some cases, the amino acid sequence  
of a functional equivalent exhibits approximately 50%  
identity with the amino acid sequence of the hsp; and in  
some cases, the amino acid sequence of a functional  
20 equivalent exhibits approximately 75% identity with the  
amino acid sequence of the hsp. In a particular  
embodiment, the amino acid sequence of a functional  
equivalent exhibits approximately 95% identity with the  
amino acid sequence of the hsp.

25 Any suitable hsp can be used in the methods of the  
present invention. The hsp for use in the present  
invention can be, for example, a mycobacterial heat shock  
protein, a human heat shock protein, a yeast heat shock  
protein, a bacterial heat shock protein, a nonhuman  
30 mammalian heat shock protein, an insect heat shock protein  
or a fungal heat shock protein. In one embodiment, the  
heat shock protein is a mycobacterial heat shock protein  
such as hsp65, hsp70, hsp60, hsp71, hsp90, hsp100, hsp10-  
12, hsp20-30, hsp40 and hsp100-200.

-8-

The hsp can be conjugated or joined to any moiety which is not generally able to enter cells on its own or which enters cells on its own only to a limited extent. The moiety can be a protein, peptide, lipid, carbohydrate, glycoprotein and/or small organic molecule. In a particular embodiment, the moiety is a functional moiety. That is, the moiety has biological activity upon entry into the cell. For example, the moiety can be a functional enzyme, hormone, protease, toxin, toxoid and/or cytokine.

Since intact proteins in the extracellular medium do not ordinarily penetrate into a cell's cytosol, soluble proteins typically fail to stimulate mice to produce CTL (Braciale, T.J. et al., *Immunol. Rev.*, 98:95-114 (1987)), although there are exceptions (Jondal, M. et al., *Immunity*, 5:295-302 (1996)). In comparison with other proteins, the soluble heat shock protein termed gp96 is an unusually effective stimulator of CD8 CTL (Udono, H. et al., *Proc. Natl. Acad. Sci. USA*, 91:3077-81 (1994)). Mice injected with gp96 isolated from tumor cells (donor cells) produce CTL that are specific for donor cell peptides in association with the responder mouse's class I MHC proteins (Udono, H. & Srivastava, P.K., *J. Immunol.*, 152:5398-5403 (1994); Arnold, D. et al., *J. Exp. Med.*, 182:885-889 (1995)). Since donor peptides are bound noncovalently by the isolated hsp protein, the results suggest that the hsp molecules are capable of delivering noncovalently associated peptides to MHC-1 proteins of other (recipient) cells, including antigen presenting cells.

The noncovalently bound peptide-gp96 complexes which are purified from a tumor cell appear to represent a broad array of proteins expressed by the cell (Arnold, D. et al., *J. Exp. Med.*, 186:461-466 (1997); Li, Z. & Srivastava, P.K., *Embo J*, 12:3143-3151 (1993)). In contrast, recombinant hsp fusion proteins in which specific proteins of interest are covalently linked to the hsp provide a

-9-

well-characterized polypeptide which lack extran  
peptides. In addition, a large protein fragment alan.  
linked to the hsp is an especially rich source of any  
different naturally processed peptides. Peptide sura  
5 of this kind, derived from specific antigens of a host,  
are particularly suitable for forming intracellular  
peptide-MHC complexes with the highly diverse MHC proteins  
found in different individuals of genetically outbred  
populations.

10 As described herein, a recombinant hsp70 protein  
expression vector that permits diverse proteins and  
peptides to be fused to the amino terminus of mycobacterial  
hsp70 was used to investigate whether soluble hsp70 fusion  
proteins could be utilized to elicit MHC class-I restricted  
15 CD8<sup>+</sup> CTL. Previously it has been shown that M.  
tuberculosis hsp70 can be used as an adjuvant-free carrier  
to stimulate the humoral and cellular response to a  
full-length protein that is covalently linked to the hsp  
(Suzue, K. & Young, R.A., *J. Immunol.*, 156:873-879 (1996)).

20 As demonstrated herein, a soluble hsp70 fusion protein  
having a large fragment of chicken ovalbumin as fusion  
partner, in the absence of adjuvants, stimulates H-2<sup>b</sup> mice  
to produce ovalbumin-specific CD8 CTL. The CTL recognized  
an immunodominant ovalbumin octapeptide, SIINFEKL (SEQ ID  
25 NO: 1), known to be a naturally processed peptide derived  
from ovalbumin expressed in mouse cells (Rotzschke, O. et  
al., *Eur. J. Immunol.*, 21:2891-2894 (1991)), in the context  
of K<sup>b</sup>. CTL from the immunized mice were as active  
cytolytically as a highly effective CTL clone (4G3) that  
30 had been raised against ovalbumin-expressing tumor cells,  
as both caused half-maximal lysis of K<sup>b</sup> target cells with  
the SIINFEKL peptide (SEQ ID NO: 1) at about the same  
concentration ( $10^{-13}$  M). The results indicate that the  
ovalbumin-hsp70 fusion protein, injected as a soluble

-10-

protein into mice, can enter the MHC class I processing pathway in antigen presenting cells and stimulate the production of CD8 CTL.

In particular, as described herein, injection of an hsp70-ovalbumin fusion protein into H-2<sup>b</sup> mice stimulated the production of CD8 CTL that recognize the immunodominant ovalbumin octapeptide, SIINFEKL (SEQ ID NO: 1), in association with K<sup>b</sup>. The immunized mice were protected against an otherwise lethal challenge with an ovalbumin-expressing melanoma tumor, and their CTL were as effective (see Figure 1B) in recognizing the SIINFEKL-K<sup>b</sup> complex as a CTL clone (4G3) that was raised against cells (EG7-OVA) in which ovalbumin is expressed and processed naturally for class I-MHC presentation. These findings clearly imply that the covalently linked fusion partner of the injected hsp fusion protein was processed in the same way as ordinary cytosolic proteins for presentation with MHC class I proteins in antigen presenting cells.

Previously it was reported that mice injected with an HIV-1 gag protein (p24) linked to hsp70 produced p24-specific T cells. Although the peptide-MHC complexes recognized by the T cells were not identified, the splenocytes from the fusion-protein immunized mice exhibited p24 antigen-dependent production of IFN- $\gamma$ , which implies the presence of Th1 helper T cells and CTL. The previous findings, taken in conjunction with the present results, show that hsp70 fusion proteins are generally useful as immunogens for stimulating CD8 CTL that are specific for peptides produced by natural proteolytic processing of the fusion partners within antigen presenting cells.

The mechanisms by which hsp70 enables covalently linked polypeptide fusion partners to gain entry into the MHC class I processing pathway and elicit CD8 CTL could be

-11-

based on: i) hsp70's ability to assist protein folding (Zhu, X. et al., *Science*, 272:1606-1614 (1995); Flynn, G. C. et al., *Nature*, 353:726-730 (1991)), and to facilitate the translocation of proteins into subcellular compartments (Cyr, D. M. & Neupert, W., in *Roles for hsp70 in protein translocation across membranes of organelles*, ed. Feige, U., Morimoto, R. I., Yahara, I. & Folia, B. S. (Birkhauser Verlag, Basel), Vol. 77, pp. 23-40 (1996); Brodsky, J. L., *Trends. Biochem. Sci.*, 21:121-126 (1996)); ii) hsp70's ability to facilitate the breakdown of intracellular proteins (Sherman, M. Y. & Goldberg, A. L., in *Involvement of molecular chaperones in intracellular protein breakdown*, eds. Feige, U., Morimoto, R. I., Yahara, I. & Folia, B. S. (Birkhauser Verlag, Basel), Vol. 77, pp. 57-78 (1996)); and iii) the high frequency of T cells directed against mycobacterial hsp70.

Hsp70 is an integral component of the protein folding machinery (Hartl, F.U. et al., *Trends Biochem. Sci.*, 19:20-25 (1994); Hartl, F.U., *Nature*, 381:571-579 (1996); Gething, M.J. & Sambrook, J., *Nature*, 355:33-45 (1992)) and functions through its ability to bind short linear peptide segments of folding intermediates. Detailed studies of the peptide-binding activity of hsp70 have shown that it has a clear preference for peptides with aliphatic hydrophobic side chains (Flynn, G.C. et al., *Nature*, 353:726-730 (1991); Rudiger, S. et al., *Embo. J.*, 16:1501-1507 (1997)). Thus hsp70 appears to transiently associate with hydrophobic protein regions and prevent protein aggregation. The kinetics of hsp70-substrate binding is governed by the ATP binding and ATPase activity of hsp70 (Flynn, G. C. et al., *Science*, 245:385-390 (1989)). The combination of the peptide and ATP binding functions of hsp70 may be involved in the efficient transfer of antigenic peptides into the MHC class I antigen presentation pathway. Hsp70 also associates with nascent

-12-

polypeptide chains as they emerge from ribosomes and are involved in stabilizing nascent polypeptides prior to their translocation into various subcellular compartments

(Beckmann, R.P. et al., *Science*, 248:850-854 (1990);

- 5 Frydman, J. et al., *Nature*, 370:111-117 (1994)), including chloroplasts, the ER, lysosomes, mitochondria, the nucleus and peroxisomes (Cyr, D.M. & Neupert, W., *Roles for hsp70 in protein translocation across membranes of organelles*, eds. Feige, U., Morimoto, R. I., Yahara, I. & Polla, B. S. (Birkhauser Verlag, Basel), Vol. 77, pp. 25-40 (1996);
- 10 Brodsky, J.L., *Trends. Biochem. Sci.*, 21:122-126 (1996)).

The present findings indicate that hsp70 also promotes delivery of covalently linked fusion polypeptides to the subcellular compartment(s) required for cell surface

- 15 presentation of peptide-MHC-1 complexes.

Hsp70's role in intracellular protein breakdown may be especially relevant for the immunogenic effectiveness of its fusion partner. Experiments with yeast cell mutants and with mammalian cell extracts have shown that, in

- 20 addition to its function in protein refolding, hsp70 serves an essential role in the degradation of certain abnormal polypeptides (Sherman, M.Y. & Goldberg, A.L., *Involvement of molecular chaperones in intracellular protein breakdown*, eds. Feige, U., Morimoto, R.I., Yahara, I. & Polla, B.S.

- 25 (Birkhauser Verlag, Basel), Vol. 77, pp. 57-78 (1996);

Nelson, R.J. et al., *Cell*, 71:97-105 (1992)). Thus, if hsp70 fails to refold a denatured protein, it can

facilitate its degradation by the cell's proteolytic machinery. In eukaryotes, hsp70 is essential for the

- 30 ubiquitination of certain abnormal and regulatory proteins and thus in the breakdown of polyubiquitinated polypeptides by the 26S proteasome (Sherman, M.Y. & Goldberg, A.L.,

*Involvement of molecular chaperones in intracellular protein breakdown*, eds. Feige, U., Morimoto, R.I., Yahara,

- 35 I. & Polla, B.S. (Birkhauser Verlag, Basel), Vol. 77, pp.



-13-

57-78 (1996)). The peptides generated by the proteases in the cytosol appear to be the primary source of the peptides that are translocated into the ER for association with class I. Thus proteins that are linked to hsp70 may be ubiquitinated and processed especially well for presentation with MHC-I proteins.

Immune responses to hsp70 have been detected following exposure to a broad spectrum of infectious agents (Selkirk, M.E. et al., *J. Immunol.*, 143:399-403 (1989); Hedstrom, T. et al., *J. Exp. Med.*, 165:1430-1435 (1987); Young, D. et al., *Proc. Natl. Acad. Sci. USA*, 85:4267-4270 (1988)). In addition, anti-hsp70 immune responses were induced in infants by the trivalent vaccine against tetanus, diphtheria and pertussis (Del Giudice, G. et al., *J. Immunol.*, 150:2025-2032 (1993)). It seems that the immune system is routinely stimulated to respond to hsp70 and such stimulation may cause an expansion of hsp70-reactive cells. The cellular responses to mycobacterial hsps are profound; limiting dilution analysis indicates that 20% of the murine CD4<sup>+</sup> T lymphocytes that recognize mycobacterial antigens are directed against hsp60 alone (Kaufmann, S.H. et al., *Eur. J. Immunol.*, 17:351-357. (1987)). The high frequency with which human CD4<sup>+</sup> T cell clones directed against mycobacterial hsp70 and hsp60 have been detected suggests that these hsps are also major targets of the cellular response in humans (Munk, M.E. et al., *Eur. J. Immunol.*, 18:1835-1838 (1988)). Thus, although soluble proteins administered in the absence of adjuvant do not typically elicit CD8 CTL, it is likely that the abundant hsp70-reactive helper T cells are involved in facilitating the unusually efficient CTL response against the soluble hsp70 fusion protein.

Another hsp, gp96, isolated from various tumors and tumor cell lines, has previously been shown to be a potent

-14-

immunogen for eliciting CD8 CTL. Gp96's effectiveness derives from i) the many peptides that remain bound noncovalently to the protein when isolated from cells (Arnold, D. et al., *J. Exp. Med.*, 186:461-466 (1997); Li, Z. & Srivastava, P.K. *Embo. J.*, 12:3143-3151 (1993)); and ii) its ability to facilitate the transfer of those peptides to MHC-1 proteins of "professional" antigen presenting cells (Suto, R. & Srivastava, P.K., *Science*, 269:1585-1588 (1995)). Detailed studies of the peptide-binding activity of hsp70 has shown that it has a clear preference for peptides over 7 amino acids in length and those with aliphatic hydrophobic side chains (Flynn, G.C. et al., *Nature*, 353:726-730 (1991); Rudiger, S. et al., *Embo. J.*, 16:1501-1507 (1997)). Although gp96 can bind many different peptides (Arnold, D. et al., *J. Exp. Med.*, 182:885-889 (1995); Udono, H. & Srivastava, P.K., *J. Exp. Med.*, 178:1391-1396 (1993); Nieland, T.J. et al., *Proc. Natl. Acad. Sci. USA*, 93:6135-6139 (1996)), studies with hsp70, as well as general considerations, indicate that no protein can serve as a universal receptor for all peptides. Recombinant hsp70 fusion proteins, in contrast, are thus likely to provide a richer source of peptides available for binding to diverse MHC molecules.

Many different proteins can be linked to hsp70 and the fusion proteins studied so far are effective immunogens in the absence of adjuvants. Hsp70 fusion proteins are thus attractive candidates for vaccines intended to stimulate CD8 CTL in humans.

As also described herein, the ability of hsp fusion vaccines to elicit MHC class I-restricted CTLs against the attached protein moiety indicates that the fusion protein is able to enter cells, as an intact molecule, and find its way into the class I antigen presentation pathway. Antigens such as ovalbumin cannot elicit a CTL response without being fused to hsp70, indicating that the heat

-15-

shock protein is necessary for cellular entry. This ability of hsps to enter cells can be used to deliver molecules that normally cannot enter cells on their own. For example, whole proteins or peptides which typically do not enter cells efficiently, but which have functional capacities once inside cells, could be fused to a heat shock protein in order to efficiently introduce them into cells. Similarly, chemicals which do not enter cells efficiently can be introduced into target cells by being fused to hsps. If necessary, the fusion protein can be engineered to become digested with a cellular protease to release a functional molecule from the fusion once it enters the cell.

Thus, the methods of the present invention can be used therapeutically or diagnostically to deliver a moiety (one or more), which is not generally able to enter cells or which enters cells only to a limited extent, into cells or into cells of an individual. In addition, the methods of the present invention can be used to deliver a moiety to a tissue or organ (e.g., of an individual). In a particular embodiment, the cells, tissues or organs are mammalian (e.g., murine, canine, feline, bovine, monkey and human) cells, tissues or organs.

In the method of the present invention wherein a moiety is delivered into mammalian cells, tissues or organs, for therapeutic purposes, an effective amount of the complex comprising the moiety of interest linked to a hsp is administered to the mammalian cell, tissue or organ. An "effective amount" is an amount such that when administered, it results in delivery of the complex comprising the moiety linked to the hsp into the cell, tissue or organ. In addition, the amount of the complex used to deliver a moiety into a cell, tissue or organ will vary depending on a variety of factors, including the moiety being delivered, the size, age, body weight, general

-16-

health, sex and diet of the individual, and the time of administration, duration or particular qualities of the condition being treated therapeutically.

Various delivery systems can be used to administer the complex to cells, tissues or organs. Methods of introduction include, for example, subcutaneous, intramuscular, intraperitoneal, intravenous, intradermal, intranasal, epidural and oral routes. Any other convenient route of administration can be used (infusion of a bolus injection, infusion of multiple injections over time, absorption through epithelial or mucocutaneous linings such as oral, mucosa, rectal or intestinal mucosa).

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.

#### EXEMPLIFICATION

##### Materials and Methods

##### 20 Expression Vector Constructs

The DNA fragment containing the *M. tuberculosis* hsp70 coding sequence was synthesized by PCR using DNA purified from  $\lambda$ gt11 clones Y3111 and Y3130 as a template (Young, D. B., Kent, L. & Young, R. A., *Infect. Immun.*, 55:1421-1425 (1987)). The complete coding sequence of hsp70 was synthesized by using the upstream primer oKS63 (5'GCCCCGGGATCCATGGCTCGTGCGGTCTCGGGAT3') (SEQ ID NO: 3) containing a *Bam*HI site immediately before the hsp70 coding sequence and the downstream primer oKS79 (5'GCGGAATTCTCATCAGCCGAGCCGGGGT3') (SEQ ID NO: 4) containing an *Eco*RI site immediately after the last coding sequence of hsp70. The DNA fragment containing the ovalbumin coding sequence was synthesized by PCR using plasmid pOv230 (McReynolds, L. et al., *Nature*, 273:723-728

-17-

(1978)) as a template. The upstream primer pKS73 (5'GCGGATCCATATGGTTCCTTCAGCCAGCTCCGTGG3') (SEQ ID NO: 5) contained a NdeI site immediately before amino acid 161 of ovalbumin and the downstream primer pKS82 (5'GCAGGATCCCTCTTCCATAACATTAG3') (SEQ ID NO: 6) contained a BamHI site immediately after amino acid 276 of ovalbumin. Another downstream primer containing a BamHI site pKS80 (5'GCTGAATTCTTACTCTTCCATAACATTAG3') (SEQ ID NO: 7), included a translation stop codon immediately after amino acid 276 of ovalbumin.

Construction of the vector used to produce hsp70 alone, pKS74, has been previously described (Suzue, K. & Young, R. A., *J. Immunol.*, 156:873-879 (1996)). The vector pKS11h was made by modifying the plasmid vector pET11 (Studier, F. W. et al., *Methods Enzymol.*, 185:60-89 (1990)) with a histidine tag coding sequence and with the polylinker from pET17b. Plasmid pKS28 was made by subcloning the DNA encoding amino acids 161 to 276 of ovalbumin into the NdeI and BamHI sites of pKS11h. Plasmid pKS76 was created by subcloning ovalbumin (161-276) and hsp70 into the NdeI and BamHI sites of pKS11h.

#### Protein Purification

Cultures of BL21(DE3)pLysS (Studier, F. W. et al., *Methods Enzymol.*, 185:60-89 (1990)) were grown and induced with 0.5 mM isopropylthiogalactoside (IPTG). Hsp70 and ova-hsp70 proteins were both purified as inclusion bodies, refolded stepwise in guanidine and subsequently purified by ATP affinity chromatography as previously described (Suzue, K. & Young, R. A., *J. Immunol.*, 156:873-879 (1996)). Protein purity was verified by SDS-PAGE and protein fractions were pooled and dialyzed against PBS. Protein concentrations were determined by the bicinchoninic acid assay (Pierce, Rockford, IL).

-16-

## Peptides

The peptides SIINFELK (corresponding to ovalbumin amino acids 258-276) (SEQ ID NO: 1) and RSTVTQGL (corresponding to the vesicular stomatitis virus nucleoprotein amino acids 324-332) (SEQ ID NO: 2), were synthesized by the Biopolymers Facility at the Center for Cancer Research at the Massachusetts Institute of Technology. Peptides were stored as 1 mg/ml stock solutions in PBS.

## 10 Mice and Immunizations

Seven-eight week old female C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, Maine) and Taconic Farms (Germantown, NY). Mice were immunized i.p. on day 0 and s.c. on day 14 with 120 pmoles of purified protein in

15 PBS.

## Cell lines

EL4 (H-2<sup>b</sup>) thymoma cells, from the American Type Culture Collection (ATCC, Rockville, MD), were grown in RPMI 1640/10% FCS. E.G7-OVA cells (ovalbumin transfected EL4 cells) (Moore, M. W. et al., Cell, 54:777-785 (1988)) were cultured in RPMI 1640/10% FCS in the presence of 320 µg of G418 per ml. The human cell line T2, is a TAP-deficient, T-B lymphoblastoid fusion hybrid. The K<sup>b</sup> transfected clone, T2-K<sup>b</sup>, a generous gift from P. Cresswell, was cultured in RPMI 1640/10% FCS in the presence of 320 µg of G418 per ml. The CTL clone 4G3 was maintained by weekly restimulation with irradiated E.G7-OVA cells in RPMI 1640/10% FCS/5% rat Con A supernatant (Walden, P. R. & Eisen, H. N., Proc. Natl. Acad. Sci. USA, 87:9015-9019 (1990)). The C57BL/6-derived melanoma B16 and the ovalbumin-transfected B16 clone, M05, (Falo, L., Jr., et al., Nat. Med., 1:649-653 (1995)) were generously

-19-

provided by L. Rothstein and L. Sigal. The B16 cells were grown in RPMI 1640/10% FCS and the M15 cells were grown in the presence of 2.0 mg of G418 and 40 µg of hygromycin/ml.

#### 5 IFN- $\gamma$ ELISA

- Spleens were removed from mice 10 days after the last injection. The spleens from 3-10 mice in each treatment group were pooled. Single-cell suspensions were prepared by grinding tissue through a sterile nylon mesh.
- 10 Erythrocytes were removed by suspending the cells in pH 7.2 lysis buffer (0.15 M  $\text{NH}_4\text{Cl}$ , 1 M  $\text{KHCO}_3$ , 0.1 mM  $\text{Na}_2\text{EDTA}$ ) and rinsing the cells two times with RPMI 1640 media. Splenocytes were then cultured at  $1 \times 10^7$  cells/ml in 96-well round bottom microculture plates in RPMI 1640,
- 15 supplemented with 10% FCS and 50 µM 2-ME at 37°C in 5%  $\text{CO}_2$ . The cells were stimulated with recombinant ovalbumin (10 µg/ml), SIINFEL peptide (SEQ ID NO: 1) (10 µg/ml), RGVYQGL (SEQ ID NO: 2) (10 µg/ml) or with Con A (5 µg/ml). Cell culture supernatants were removed at 72 h. A sandwich
- 20 ELISA using paired monoclonal antibodies (Endogen, Cambridge, MA) was used to measure IFN- $\gamma$ .

#### CTL assay

- Single-cell suspensions of splenocytes were prepared as above.  $25 \times 10^6$  splenocytes were cultured with  $5 \times 10^6$
- 25 irradiated (15,000 rads) E.G7-CVA cells in RPMI 1640 supplemented with 10% FCS, 50 µM 2-ME, 1 mM sodium pyruvate and 100 µM non-essential amino acids. After 6-7 days in culture, splenocytes were purified by Ficoll-Paque (Pharmacia, Piscataway, NJ) density centrifugation and then
- 30 utilized as effector cells.

Target cells were labeled with 100 µCi [ $^{51}\text{Cr}$ ] at 37°C for 1-2 h. For peptide sensitization of target cells, 50

-20-

$\mu$ g of peptide was added to the target cells (300  $\mu$ g/ml final peptide concentration) during the labeling period. The cells were then rinsed and 5000 [ $^{51}\text{Cr}$ ]-labeled targets and serial dilutions of effector cells were incubated at various E:T ratios in 96 well U-bottom plates at 37°C. For peptide titration assays, the target cells were not pulsed with any peptide during the [ $^{51}\text{Cr}$ ]-labeling period and instead, the peptide was directly added to the 96 well U-bottom plate at final concentrations of  $10^{-10}$  M to  $10^{-14}$  M. Supernatants were harvested after 4-6 h and the radioactivity was measured in a gamma counter. % Specific lysis was calculated as equal to  $100 \times [(\text{release by CTL-spontaneous release}) / (\text{maximal release-spontaneous release})]$ . Maximal release was determined by addition of 1% Triton X-100 or by resuspending target cells.

#### In vitro depletion or enrichment of lymphocyte subpopulations

Splenocytes were cultured with irradiated E.G7-OVA cells and purified by Ficoll-Paque (Pharmacia) density centrifugation as described above. Cells were resuspended in cold PBS with 1% FCS and incubated with anti-mouse CD4 (L3T4) microbeads or with anti-mouse CD8a (Ly-2) microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) for 20 min. at 4°C. For cell depletion, the cells were applied on to a Mini MACS column (Miltenyi Biotech) with an attached flow resistor. The cells from the flow-through were collected and used as effector cell in the cytolytic assay. For positive selection of CD8 cells, the cells were applied on to a Mini MACS column without a flow resistor. The column was rinsed and the cells adhering to the column were released by removing the column from the magnetic holder. The positively selected cells were then used as effector cells in the cytolytic assay. The effectiveness of



-11-

positive and negative selection of cells was verified by flow cytometry using phycoerythrin conjugated anti-mouse CD4 and fluorescein isothiocyanate conjugated anti-mouse CD8a antibodies (Pharmingen, San Diego, CA).

#### 5 Tumor protection assay

- C57BL/6 mice were injected i.p. with 120 pmoles of ova or ova-hsp70 without adjuvant and boosted s.c. 2 weeks later. Ten days after the last immunization the mice were injected s.c. on the right flank with  $1 \times 10^5$  MO5 tumor cells or with  $1 \times 10^5$  B16 tumor cells. As a control, unimmunized mice were also inoculated with the tumor cells. Five to ten mice were used for each experimental group. On the day of the tumor challenge, the B16 and MO5 cells were harvested by trypsinization and rinsed three times in PBS.
- 15 The cells were resuspended in PBS and administered s.c. in a volume of 0.1 ml. Tumor growth was assessed by measuring the diameter of the tumor in millimeters (recorded as the average of two perpendicular diameter measurements). Mice that became moribund were sacrificed. Consistent results
- 20 were observed in three separate experiments.

#### RESULTS

##### Purified recombinant proteins

- A recombinant system developed to permit production of *M. tuberculosis* hsp70 fusion proteins in *E. coli* (Suzue, K. & Young, R. A., *J. Immunol.*, 156:873-879 (1996)) was
- 25 utilized to attach amino acids 161 to 276 of ovalbumin to the N-terminus of *M. tuberculosis* hsp70. A comparable recombinant ovalbumin protein (amino acids 161 to 276) was also produced. The selected portion of ovalbumin contains
- 30 the immunodominant epitope SIINFELK (SEQ ID NO: 1) recognized by CTL in association with  $K^b$  (Rotzschke, C. et al., *Eur. J. Immunol.*, 21:2891-2894 (1991); Carbone, F. R.

-22-

- & Bevan, M. J., *J. Exp. Med.*, 169:603-612 (1989)). The ovalbumin hsp70 fusion protein and the ovalbumin (aa 161-276) protein were expressed at high levels in *E. coli*. These proteins were purified as inclusion bodies, refolded  
5 in vitro, and further purified by column chromatography. The purity of the recombinant proteins was assessed by SDS-PAGE. *E. coli* cell lysates and purified proteins were examined by SDS-PAGE and proteins were visualized by Coomassie staining. The gel contained crude extracts from  
10 IPTG-induced *E. coli* containing pKS28 (ova 161-276) and from IPTG-induced *E. coli* containing pKS76 (ova-hsp70), and the purified proteins ova 161-276 and ova-hsp70. Examination of commercial preparations of crystallized and high grade ovalbumin by SDS-PAGE and silver staining  
15 revealed that they are highly contaminated with low molecular weight polypeptides. For this reason, only the highly purified recombinant ovalbumin (aa 161-276) protein, referred to below simply as ovalbumin, was used in these studies.
- 20 Immunization of mice with hsp70 fusion protein in PBS elicits T cell responses against the attached antigen
- Whether mice injected with soluble protein without adjuvant could be primed to produce anti-ovalbumin T cells was investigated (Figure 1A). C57BL/6 mice were inoculated  
25 i.p. with 120 pmoles of ovalbumin (ova) or with 120 pmoles of ovalbumin-hsp70 fusion protein (ova-hsp70) in PBS. A second equivalent dose was given s.c. at two weeks. A third group of mice was injected with 120 pmoles of ovalbumin-p24 gag fusion protein (ova-p24), purified as  
30 described in (Suzue, K. & Young, R. A., *J. Immunol.*, 156:873-879 (1996)), in order to examine the immune responses elicited by administering ovalbumin covalently linked to a protein other than hsp70, in the absence of adjuvant. Splenocytes of immunized mice were removed ten

-23-

- days after the s.c. immunization and for each group, 5-10 spleens were pooled and splenocytes from these mice were cultured in vitro for 6 days with irradiated E.G7-OVA cells (syngeneic EL4 cells transfected with ovalbumin) without added interleukins (Moore, W. e. Cell, 54:777-785 (1988)). The cultured cells were then used as effector cells in CTL assays. Cells from mice infected with ovalbumin protein or with ovalbumin-p24 fusion protein were unable to lyse T2-K<sup>b</sup> target cells or T2-K<sup>b</sup> cells pulsed with SIINFEKL peptide (SEQ ID NO: 1). In contrast, effector cells from mice primed with ovalbumin-hsp70 fusion protein were able to lyse T2-K<sup>b</sup> cells pulsed with SIINFEKL peptide (SEQ ID NO: 1). See Figure 1A wherein the splenocyte cultures derived from mice immunized with ova □, ova-p24 ▽ and ova-hsp70 ■, which were used as effector cells in a standard cytotoxicity assay, is shown. The following <sup>51</sup>Cr-labeled target cells were used: T2-K<sup>b</sup> cells \_\_\_\_\_ and T2-K<sup>b</sup> pulsed with SIINFEKL peptide \_\_\_\_\_ at 300 µg/ml.
- Results obtained with other target cells also show that the anti-ovalbumin CTL recognized SIINFEKL (SEQ ID NO: 1) in association with K<sup>b</sup>. Splenocytes from ovalbumin-hsp70 immunized mice were able to lyse both E.G7-OVA target cells and EL4 cells pulsed with SIINFEKL (SEQ ID NO: 1) peptide but were unable to lyse EL4 cells in the absence of peptide or EL4 cells pulsed with another K<sup>b</sup>-binding peptide (RGYVYQGL (SEQ ID NO: 2), from vesicular stomatitis virus, (Van Bleek, G. M. & Nathenson, S. G., Nature, 348:213-216 (1990))).
- To assess the effectiveness of the CTL from ova-hsp70-immunized mice, they were tested after 6 days in culture in cytolytic assays using T2-K<sup>b</sup> as target cells and SIINFEKL (SEQ ID NO: 1) at various concentrations. For purposes of comparison, the assay included a

-24-

well-characterized CTL clone (4G3) that recognizes the SIINFEKL-K<sup>b</sup> complex. As shown in Figure 1B, half-maximal lysis was obtained with both the CTL line and the 4B3 clone at about the same peptide concentration, approximately  $5 \times 10^{-13}$  M. Thus CTL from the ova-hsp70 immunized mice and the clone against the ovalbumin-expressing tumor (E.G7-OVA) were equally effective in terms of the SIINFEKL (SEQ ID NO: 1) concentration required for half-maximal lysis. It may be noted that in Figure 1B the ratio of 4G3 cells to target cells (E:T ratio) was 5:1, whereas for the CTL line this ratio was 80:1. While the E:T ratio has a large impact on the maximal lysis of target cells at 4 hr, changing this ratio over an 80-fold range (1:1 to 80:1) has a negligible effect on the peptide concentration required for half-maximal lysis.

Next, that the cytolytic activity of the CTL line from ova-hsp70 immunized mice was due to CD8<sup>+</sup> T cells was verified (Figures 2A-2C). C57BL/6 mice were injected i.p. with 120 pmoles of ova or ova-hsp70 without adjuvant and boosted s.c. with the same amounts of these proteins 2 weeks later. Mice were sacrificed 10 days after the boost and for each mouse group, 5-10 spleens were pooled and splenocytes were incubated for 6 days in the presence of irradiated E.G7-OVA cells. Prior to performing the cytotoxicity assay, the effector cells were negatively or positively selected for CD4<sup>+</sup> cells or CD8<sup>+</sup> cells using paramagnetic antibodies (see Materials and Methods). Splenocyte cultures were either depleted of CD4<sup>+</sup> cells (CD4-CD8<sup>+</sup>) (Figure 2A), depleted of CD8<sup>+</sup> cells (CD4<sup>+</sup> CD8<sup>-</sup>) (Figure 2B) or were enriched for CD8<sup>+</sup> cells (CD8<sup>+</sup>) (Figure 2C). A MACS column to separate the CTL line into T cell subsets (see Materials and Methods) was used. CTL activity was unaffected by removing CD4<sup>+</sup> cells, but it was completely abrogated by removing CD8<sup>+</sup> cells. Retrieval of

-35-

the CD8<sup>+</sup> cells from the MACS column led to recovery of cytolytic activity. The results were the same when target cells were EL4 cells incubated with SIINFEKL (SEQ ID NO: 1) or ovalbumin expressing EL4 cells (E.37-OVA). Thus, administration of ovalbumin-hsp70 fusion protein, but not ovalbumin alone, elicits CD8<sup>+</sup> CTL specific for SIINFEKL (SEQ ID NO: 1).

The lower level of cytolytic activity in Figures 3A-3C relative to Figure 1A and Figure 1B reflects the different target cells used. T2-K<sup>b</sup> cells (Figures 1A-1B) and EL4 cells (Figures 2A-2C) have approximately the same high level of cell surface K<sup>b</sup> (roughly 100,000 molecules per cell), but the peptide transporter (TAP) is defective in T2-K<sup>b</sup> (Anderson, K. S. et al., *J. Immunol.*, 151:3407-3419 (1993)), and not in EL4. Hence, at a given free concentration of SIINFEKL (SEQ ID NO: 1) the target cell epitope density (number of SIINFEKL K<sup>b</sup> complexes per cell) is much greater on T2-K<sup>b</sup> than EL4 cells.

Hsp70 must be covalently coupled to ovalbumin to engender antiovalbumin T cell responses

Next, it was examined whether the covalent fusion of hsp70 to ovalbumin was necessary to elicit cellular responses to ovalbumin or whether the same results could be obtained if the two proteins were simply mixed but not covalently attached (Figures 3A-3B). Mice were injected with 120 pmoles of ovalbumin-hsp70 fusion protein, with 120 pmoles of ovalbumin, or with 120 pmoles of hsp70 mixed with 120 pmoles of ovalbumin. Ten days after the boost 5-10 spleens from each mouse group were pooled and processed. The level of IFN- $\gamma$  secreted by the splenocytes in response to restimulation with ovalbumin in vitro was measured by ELISA. Splenocytes from mice immunized with ovalbumin alone or with a mixture of ovalbumin and hsp70 proteins

-26-

produced less than 6 ng/ml IFN- $\gamma$  in response to stimulation with SIINFEKL peptide (SEQ ID NO: 1) or ovalbumin (Figure 3A). In contrast, splenocytes from mice injected with the ovalbumin-hsp70 fusion protein secreted substantially higher levels of IFN- $\gamma$  when restimulated in vitro with SIINFEKL peptide (SEQ ID NO: 1) or ovalbumin. The release of IFN- $\gamma$  was ovalbumin specific, since splenocytes cultured in media alone or with control RGYVYQGL peptide (SEQ ID NO: 7) secreted low levels of IFN- $\gamma$ .

Similar results were obtained by cytolytic assays. See Figure 3B wherein splenocyte cultures from mice immunized with recombinant ova  $\square$ , ova-hsp70 fusion protein  $\blacksquare$  or with a mixture of ova and hsp70 proteins  $\Delta$ , were used as effector cells in a standard cytotoxicity assay is shown. The following  $^{51}\text{Cr}$ -labeled target cells were used: E.G7-OVA  $\text{---}$  and EL4 cells alone  $\text{---}$ . Ovalbumin-specific CTL were produced by mice injected with the ovalbumin-hsp70 fusion protein but not by those injected with a mixture of ovalbumin with hsp70.

Immunization of mice with ovalbumin-hsp70 protein without adjuvant engenders protective immunity to M05 tumor challenge

The M05 cell line, which is a B16 melanoma cell line transfected with ovalbumin expressing DNA, presents the immunodominant SIINFEKL peptide (SEQ ID NO: 1) in association with K<sup>b</sup> on the cell surface (Falo, L., Jr., et al., Nat. Med., 1:649-653 (1995)). Using this tumor it was determine whether the immune response induced by ovalbumin-hsp70 fusion protein is sufficient to engender protective tumor immunity. Mice were injected i.p. with 120 pmoles of ovalbumin or ovalbumin-hsp70 without adjuvant and boosted s.c. 2 weeks later. Ten days later the mice were injected s.c. on the right flank with  $1 \times 10^5$  M05

-27-

tumor cells or with  $1 \times 10^5$  B16 tumor cells. As an additional control, naive mice were also injected with the tumor cells.

All mice challenged with tumor cells were monitored for tumor growth and growth was recorded as the average tumor diameter in millimeters (Figures 4A-4B). Twenty days following the M05 tumor challenge, the average tumor diameter in the control and the ovalbumin immunized mice was greater than 15 mm. Because the control and ovalbumin immunized mice began dying 21 days after the tumor challenge, tumor growth was not recorded beyond 21 days. In contrast to the control and the ovalbumin-immunized mice, no tumors were detected in the ovalbumin-hsp70 immunized mice 21 days after the tumor challenge. All groups of mice (control, ovalbumin-immunized or ovalbumin-hsp70 immunized) which were challenged with the B16 tumor cells developed tumors and became moribund by 21 days after the tumor challenge.

The survival of mice was recorded as the percentage of mice surviving following the tumor challenge (Figure 4C). Mice which appeared moribund were sacrificed. Forty days after the M05 tumor challenge, none of the control mice and only 10% of the ovalbumin-immunized mice had survived. In contrast, 80% of the ovalbumin-hsp70 immunized mice had survived. These experiments demonstrate that immunization of mice with the ovalbumin-hsp70 fusion protein, but not with the ovalbumin protein alone, induces ovalbumin specific protective tumor immunity.

-26-

Administering Ovalbumin-hsp70 Fusion Protein Containing either the ATP Binding or the Peptide Binding Domain of hsp70 is Sufficient to Elicit anti-ovalbumin T Cell Responses

5 Whether the peptide binding or the ATP binding domain of hsp70 was sufficient for eliciting T cell responses to the attached ovalbumin antigen was investigated. It is possible that since the ATPase and ATP binding functions of the hsp70 protein were not essential for its adjuvant-free  
10 carrier function, that the presence of this function domain of hsp70 is unnecessary when utilizing the ovalbumin-hsp70 fusion protein to elicit anti-ovalbumin T cell responses. The amino terminal 44 kD portion of hsp70 has been characterized as the ATP binding domain with ATPase  
15 activity and the carboxyl terminal portion of hsp70 binds polypeptide substrates. Recombinant fusion proteins were produced with the ATP binding domain of hsp70 attached to ovalbumin (ovalbumin-NH<sub>2</sub> hsp70) and the peptide binding domain of hsp70 attached to ovalbumin (ovalbumin CO<sub>2</sub>H  
20 hsp70). These proteins were purified from *E. coli* as inclusion bodies, refolded and purified using NTA-Ni<sup>2+</sup> chromatography.

The T cell responses to ovalbumin were assessed after injecting mice with ovalbumin-NH<sub>2</sub> hsp70 or with ovalbumin-  
25 CO<sub>2</sub> hsp 70 fusion protein in saline solution. Levels of IFNg secreted by the splenocytes in response to OVA8 peptide was 22 ng/ml in the ovalbumin-NH<sub>2</sub> hsp70 group and was 19 ng/ml in the ovalbumin-CO<sub>2</sub>H hsp70 group. When splenocytes were stimulated with the ovalbumin protein  
30 antigen, the IFNg levels were 38 ng/ml in the ovalbumin-NH<sub>2</sub> hsp70 group and was 29 ng/ml in the ovalbumin-CO<sub>2</sub>H hsp70 group. In the cytolytic assay, the effector cells from both of these groups were able to effectively lyse OVA8 pulsed EL4 target cells and E.G7-OVA target cells but not



the EL4 control cells. Administering soluble protein with either the amino or the carboxyl terminal portion of hsp70 fused to ovalbumin is sufficient to elicit a strong T cell responses.

## 5 DISCUSSION

Mice immunized with heat shock proteins (hsp) isolated from mouse tumor cells (donor cells) produced CD8 cytotoxic T lymphocytes (CTL) that recognized donor cell peptides in association with the MHC class I proteins of the responding mouse. The CTL are likely induced because peptides noncovalently associated with the isolated hsp molecules can enter the MHC class I antigen processing pathway of professional antigen presenting cells. Using a recombinant heat shock fusion protein with a large fragment of ovalbumin covalently linked to mycobacterial hsp70, it has been shown herein that when the soluble fusion protein was injected without adjuvant into H-2<sup>b</sup> mice, CTL were produced that recognized an ovalbumin-derived peptide, SIINFEKL (SEQ ID NO: 1), in association with K<sup>b</sup>. The peptide is known to arise from natural processing of ovalbumin in H-2<sup>b</sup> mouse cells, and both CTL from the ova-hsp70-immunized mice and a highly effective CTL clone (4G3) raised against ovalbumin-expressing EL4 tumor cells (EG7-OVA), were equally effective in terms of the concentration of SIINFEKL (SEQ ID NO: 1) required for half-maximal lysis in a CTL assay. The mice were also protected against lethal challenge with ovalbumin-expressing melanoma tumor cells. Because large protein fragments or whole proteins serving as fusion partners can be cleaved into short peptides in the MHC class I processing pathway, hsp fusion proteins of the type described herein can be used to deliver moieties or molecules (e.g., proteins, peptides, lipids) which are not

-30-

generally able to enter cells or enter cells only to a limited extent, into cells.

#### EQUIVALENTS

While this invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.

-31-

## CLAIMS

We claim:

1. A method of delivering a moiety of interest into a cell comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell.
2. The method of Claim 1 wherein the heat shock protein is selected from the group consisting of:  
mycobacterial heat shock proteins, human heat shock proteins, yeast heat shock proteins, bacterial heat shock proteins, nonhuman mammalian heat shock proteins, insect heat shock proteins and fungal heat shock proteins.
3. The method of Claim 2 wherein the heat shock protein is a mycobacterial heat shock protein selected from the group consisting of: hsp65, hsp70, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 and hsp100-200.
4. The method of Claim 3 wherein the moiety is selected from the group consisting of: proteins, peptides, lipids, carbohydrates, glycoproteins and small organic molecules.
5. A method of delivering a moiety of interest into an antigen presenting cell comprising contacting the cell with a complex comprising the moiety of interest covalently linked to a heat shock protein, under conditions appropriate for entry of the complex into the cell.

-32-

6. The method of Claim 5 wherein the heat shock protein is selected from the group consisting of:  
mycobacterial heat shock proteins, human heat shock proteins, yeast heat shock proteins, bacterial heat shock proteins, nonhuman mammalian heat shock proteins, insect heat shock proteins and fungal heat shock proteins.  
5
7. The method of Claim 6 wherein the heat shock protein is a mycobacterial heat shock protein selected from the group consisting of: hsp65, hsp70, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 and hsp100-200.  
10
8. The method of Claim 7 wherein the moiety is selected from the group consisting of: proteins, peptides, lipids, carbohydrates, glycoproteins and small organic molecules.  
15
9. A method of delivering a moiety of interest into a cell capable of taking up a complex comprising the moiety of interest covalently linked to a heat shock protein, comprising contacting the cell with the complex, under conditions appropriate for entry of the complex into the cell.  
20
10. The method of Claim 9 wherein the heat shock protein is selected from the group consisting of:  
mycobacterial heat shock proteins, human heat shock proteins, yeast heat shock proteins, bacterial heat shock proteins, nonhuman mammalian heat shock proteins, insect heat shock proteins and fungal heat shock proteins.  
25

-33-

11. The method of Claim 10 wherein the heat shock protein is a mycobacterial heat shock protein selected from the group consisting of: hsp65, hsp70, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 and hsp100-200.
12. The method of Claim 11 wherein the moiety is selected from the group consisting of: proteins, peptides, lipids, carbohydrates, glycoproteins and small organic molecules.
13. Use of a complex comprising a moiety of interest covalently linked to a heat shock protein to deliver the moiety of interest into a cell.
14. Use of a complex comprising a moiety of interest covalently linked to a heat shock protein in a method of delivering the moiety of interest into cells of an individual, wherein the method comprises contacting the cells with the complex under conditions appropriate for entry of the complex into cells.
15. Use according to Claim 14 wherein the heat shock protein is selected from the group consisting of: mycobacterial heat shock proteins, human heat shock proteins, yeast heat shock proteins, bacterial heat shock proteins, nonhuman mammalian heat shock proteins, insect heat shock proteins and fungal heat shock proteins.
16. Use according to Claim 15 wherein the heat shock protein is a mycobacterial heat shock protein selected from the group consisting of: hsp65, hsp70, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 and hsp100-200.

-34-

17. Use according to Claim 16 wherein the moiety is selected from the group consisting of: proteins, peptides, lipids, carbohydrates, glycoproteins and small organic molecules.
- 5 18. Use of a complex comprising a moiety of interest covalently linked to a heat shock protein in a method of delivering the moiety of interest into antigen presenting cells of an individual, wherein the method comprises contacting the cells with the complex under  
10 conditions appropriate for entry of the complex into cells.
19. Use according to Claim 18 wherein the heat shock protein is selected from the group consisting of: mycobacterial heat shock proteins, human heat shock  
15 proteins, yeast heat shock proteins, bacterial heat shock proteins, nonhuman mammalian heat shock proteins, insect heat shock proteins and fungal heat shock proteins.
20. Use according to Claim 19 wherein the heat shock  
20 protein is a mycobacterial heat shock protein selected from the group consisting of: hsp65, hsp70, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 and hsp100-200.
21. Use according to Claim 20 wherein the moiety is  
25 selected from the group consisting of: proteins, peptides, lipids, carbohydrates, glycoproteins and small organic molecules.
22. Use of a complex comprising a moiety of interest covalently linked to a heart shock protein in a method  
30 of delivering the moiety of interest into cells of an

-35-

individual, wherein the cells are capable of taking up the complex comprising contacting the cells with the complex, under conditions appropriate for entry of the complex into cells.

- 5 23. Use according to Claim 22 wherein the heat shock protein is selected from the group consisting of: mycobacterial heat shock proteins, human heat shock proteins, yeast heat shock proteins, bacterial heat shock proteins, nonhuman mammalian heat shock  
10 proteins, insect heat shock proteins and fungal heat shock proteins.
24. Use according to Claim 23 wherein the heat shock protein is a mycobacterial heat shock protein selected from the group consisting of: hsp65, hsp70, hsp60,  
15 hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 and hsp100-200.
25. Use according to Claim 24 wherein the moiety is selected from the group consisting of: proteins, peptides, lipids, carbohydrates, glycoproteins and  
20 small organic molecules.

**THIS PAGE BLANK (USPTO)**



1/4




FIG. 1A




FIG. 1B

**THIS PAGE BLANK (USPTO)**





FIG. 2A





FIG. 2B




FIG. 2C

**THIS PAGE BLANK (USPTO)**

3/4




FIG. 3A




FIG. 3B

**THIS PAGE BLANK (USPTO)**




FIG. 4A




FIG. 4B




FIG. 4C

**THIS PAGE BLANK (USPTO)**



# INTERNATIONAL SEARCH REPORT

National Application No.  
PC/US 98/02010

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JINDAL S: "Heat shock proteins: applications in health and disease" TRENDS IN BIOTECHNOLOGY, vol. 14, no. 1, January 1996, page 17-20 XP004035805 see abstract; figure 1 see page 19, column 2 - page 20	1-25
X	WO 95 31994 A (YEDA RES & DEV ; COHEN IRUN R (IL); FRIDKIN MATITYAHU (IL); KONEN W) 30 November 1995 see abstract; claims 1-3,6,7,18,19,21,22; examples 1-3	1-25

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

\* Special categories of cited documents:

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "C" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\* "S" document member of the same patent family

Date of the actual completion of the international search

6 July 1998

Date of mailing of the international search report

2 2.07. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to
X	WO 94 03208 A (YEDA RES & DEV ;COHEN IRUN R (IL); FRIDKIN MATITYAHU (IL); KONEN W) 17 February 1994 see abstract; claims 1-3,6-10,17,21,22; examples 3-5; tables 1,2,4 ---	1-25
A	WO 95 24923 A (SINAI SCHOOL MEDICINE ;SRIVASTAVA PRAMOD K (US); UDONO HEIICHIRO ()) 21 September 1995 see abstract; claims 18,20-22 ---	1-25
X	WO 94 29459 A (WHITEHEAD BIOMEDICAL INST) 22 December 1994 see abstract; claims 1,13; examples 2,3 see page 21, line 30 - page 22, line 35 ---	1-25
X	WO 93 17712 A (SCLAVO BIOGINE SPA) 16 September 1993 see abstract; claims 1-5,7; example 1 ---	1-25
X,P	WO 97 06821 A (SLOAN KETTERING INST CANCER ;ROTHMAN JAMES E (US); HARTL F ULRICH) 27 February 1997 see claims 1-4,12-14,20; figures 1-4; examples 1,3,10,14 ---	1-25
X	SUZUE K ET AL: "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway." PROC NATL ACAD SCI U S A, NOV 25 1997, 94 (24) P13146-51, UNITED STATES, XP002070395 see abstract; figures 1-3 see page 13148 - page 13149 ---	1-25
X	SUZUE K. ET AL: "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24" JOURNAL OF IMMUNOLOGY, vol. 156, 1996, pages 873-879, XP002070468 cited in the application see abstract; figures 1-4 see page 875 - page 876 see page 877, column 2, paragraph 5 - page 878, column 2 -----	1-25

# INTERNATIONAL SEARCH REPORT

International Search Report  
PCT/US 93/03000

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-25  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 14-25 is(are) directed to a method of treatment of the human/an body, the search has been carried out and based on the actual effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL

## H REPORT

Information on page

numbers

National Application No.

PCT/US 98/03033

Patent document cited in search report	Publication date	Patent family members	Publication date
WO 9531994 A	30-11-1995	AU 684369 B	11-11-1997
		AU 2602768 A	15-11-1993
		CA 2191201 A	30-11-1993
		EP 0760671 A	12-03-1997
		JP 10504524 T	06-05-1998
WO 9403208 A	17-02-1994	IL 102687 A	10-06-1997
		AU 683421 B	13-11-1997
		AU 4790093 A	03-02-1994
		CA 2141494 A	17-01-1994
		CZ 9500229 A	13-09-1995
		EP 0658120 A	21-06-1995
		FI 950405 A	30-03-1995
		HU 70983 A	28-11-1995
		JP 8500102 T	09-01-1996
		NO 950328 A	23-03-1995
		NZ 255143 A	26-03-1996
		PL 307297 A	15-05-1995
		SK 11295 A	13-09-1995
		US 5736146 A	07-04-1998
WO 9524923 A	21-09-1995	AU 2100995 A	03-10-1995
		CA 2185651 A	21-09-1995
		EP 0750513 A	02-01-1997
		JP 10501520 T	10-02-1998
WO 9429459 A	22-12-1994	EP 0700445 A	13-03-1996
		JP 8510756 T	12-11-1996
WO 9317712 A	16-09-1993	IT 1262896 B	22-07-1996
		AT 161425 T	15-01-1998
		CA 2131551 A	16-09-1993
		DE 69315993 D	05-02-1998
		DE 69315993 T	02-07-1998
		EP 0632727 A	11-01-1995
		JP 7504423 T	18-05-1995
WO 9706821 A	27-02-1997	AU 6849396 A	12-03-1997
		AU 6898496 A	12-03-1997
		AU 6952896 A	12-03-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inventor's name  
PCT/US 98/03013

Patent document cited in search report	Publication date	Parent family member(s)	Publication date
WO 9706821 A		WO 9706885 A	27-02-1997
		WO 9706828 A	27-02-1997

**THIS PAGE BLANK (USPTO)**